Navigation Links
Lilly Grants $4.4 Million to the WHO for MDR-TB Program Expansion
Date:3/12/2008

INDIANAPOLIS and LONDON, March 12 /PRNewswire-FirstCall/ -- Today Eli Lilly and Company announced its four-year grant of $4,384,000 to the World Health Organization (WHO) for scaling up its global capacity to manage multi- drug resistant tuberculosis (MDR-TB) programs.

The grant covers four activities, starting with the technical assistance the WHO will provide to developing countries that the Global Fund to Fight AIDS, Tuberculosis and Malaria operations do not cover. The WHO will provide assistance to some 25 countries in their clinical management of MDR-TB, infection control, laboratory facilities and community outreach. Second, the WHO will conduct workshops for health care personnel so they can better design and manage TB programs, for laboratory technicians so they can test for first and second line drug susceptibility, and for administrative personnel to record and report on TB incidence in their countries. A third component is support for training global MDR-TB experts so they can expand training in developing countries, run workshops in infection control, and strengthen laboratories for proper diagnosis and treatment. Finally, the grant will support the field-testing and evaluation of a new information system to record and report on MDR-TB rates in two countries.

"This grant represents Lilly's continued commitment to support the WHO in its goal of treating 50 million TB patients and 1.6 million MDR-TB patients by 2015. It builds upon existing WHO and Lilly program successes in curbing the MDR-TB pandemic," says Alex Azar, senior vice president of corporate affairs and communications for Lilly. "With drug resistance at an all time high, the engagement in fighting MDR-TB comprehensively is more important now than ever."

Since 2003, approximately 30,000 patients have been enrolled on treatment in WHO Green Light Committee approved projects. Country officials and healthcare personnel have consistently identified the training of human resource management a major challenge to accelerating the global scale up of MDR-TB treatment programs. Lilly funds are instrumental for in-country capacity building for MDR-TB control. Eight regional training workshops have been conducted in high TB burden areas, training some 160 senior TB officers and health workers in WHO guidelines for the programmatic management of drug resistant TB. To complement this training, Lilly supports the monitoring and delivery of technical assistance, including the production of second-line TB medications, to over 20 Green Light Committee approved projects.

"Confronting the threat of MDR-TB is a priority for WHO," said Dr. Mario Raviglione, director of the WHO Stop TB Department. "Our scale-up efforts have prompted the expansion of MDR-TB programmes in some of the world's poorest countries. I am delighted that Lilly will continue to support our goal to strengthen measures to diagnose and treat all MDR-TB patients. This commitment is an important contribution and confirms Lilly's position as a key partner in the fight to push back the spread of drug-resistant TB."

"The expansion of WHO programs joins those of the larger Lilly MDR-TB Partnership -- a five-year-old alliance of 14 public and private organisations fighting MDR-TB from every angle. We will continue to learn lessons from existing programs and improve our initiatives to best serve those suffering from MDR-TB, and to best prevent its spread," Azar said.

About Lilly

Eli Lilly and Company, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly programs is available at http://www.lilly.com and http://www.lillymdr-tb.com. C-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20071109/CLF001LOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Newly Labeled Therapies for Neuropathic Pain, Including Drugs From Pfizer and Eli Lilly, Will Drive Growth in the Chronic Pain Drug Market
2. Mental Health Parity Laudable, But House Legislation Would Put Medicaid Patients at Risk, Lilly Says
3. FDA Issues Not-Approvable Letter for Lillys Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
4. Lilly and Partners In Health, Brigham and Womens Hospital Team Up to Fight MDR-TB in Former Soviet Republics
5. Michael L. Eskew Elected to Lilly Board of Directors
6. Lilly Caps Successful Year with Strong Fourth-Quarter Results
7. Lilly Sets Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results Announcement
8. Lilly Announces Dividend Increase
9. Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy
10. International Federation-Lilly Agreement Will Allow Significant Increase in MDR-TB Programmes
11. JDRF and Lilly partner to fund research to identify beta cell biomarkers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology: